Calgary, AB – TheNewswire - January 23, 2023 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, advises that it’s addiction and mental health treatment clinic, the Kelburn Recovery Center (“Kelburn”), which operates near Winnipeg, Manitoba via a wholly-owned subsidiary of UI, has re-opened effective January 23, 2023.

Dr. Ian Rabb, UI’s Chief Clinics Officer stated “We experienced a longer than expected closure period in 2022 following on-site basement flooding damages, and the subsequent repairs and a related facility upgrade process.  It has been a transformational process both within the physical structure of the clinic as well as with the programming, staff and services offering.  Kelburn offers leading edge addiction and mental health services with care for mind, body and spirit, utilizing the most effective evidence based treatment protocols available today.  We also intend to provide ibogaine based detox therapy upon the planned eventual regulatory approval by Health Canada.  Addiction treatment is in high demand so we expect to be busy.”

About Universal Ibogaine Inc. 

UI is a life sciences company, with a mission to transform addiction treatment using medicalized ibogaine through a planned Canadian clinical trial focused on opioid use disorder, and ultimately to utilize that protocol globally through planned future licensing agreements.    UI is concurrently developing a state of the art holistic addiction treatment protocol at its Kelburn Recovery Centre that, which when paired with the planned ibogaine detox protocol, is intended to revolutionize the way we treat addiction and drastically improve the lives of individuals and families affected by addiction.  

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS  

‎This news release may contain forward-looking statements and information. Forward-looking information is frequently characterized by words such ‎as "plans", "expect", "project", "intend", "will", "believe", "anticipate", "estimate", "scheduled", ‎‎"potential", or other similar words, or statements that certain events or conditions "may", "should" or ‎‎"could" occur.  The forward-looking statements and information are based on certain key expectations ‎and assumptions made by UI.  Although UI believes that the expectations and assumptions on which the forward-‎looking statements are based are reasonable, undue reliance should not be placed on the forward-‎looking statements because UI can give no assurance that they will prove to be correct. 

Since ‎forward-looking statements address future events and conditions, by their very nature they involve ‎inherent risks and uncertainties. Actual results could differ materially from those currently anticipated ‎due to a number of factors and risks, which include, but are not limited to, risks that required ‎regulatory approvals are not obtained. The reader is cautioned that assumptions used in the ‎preparation of such information, although considered reasonable by UI at the time of ‎preparation, may prove to be incorrect and readers are cautioned not to place undue reliance on ‎forward-looking information, which speaks only to conditions as of the date hereof.  UI does not ‎undertake any obligation to release publicly any revisions to forward-looking information contained ‎herein to reflect events or circumstances that occur after the date hereof or to reflect the occurrence ‎of unanticipated events, except as may be required under applicable securities laws. ‎ 

For further information:  

Investor Relations: Dugan Selkirk, IR Manager 

dugan.selkirk@universalibogaine.com 

Related Links 

https://universalibogaine.com